Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267642 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
A Phase 2 study of Psoriatic Arthritis, sponsored by AbGenomics B.V Taiwan Branch.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT02267642: Completed Phase 2 study of Psoriatic Arthritis, sponsored by AbGenomics B.V Taiwan Branch.
NCT02267642 is a Phase 2 study of Psoriatic Arthritis that has completed, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 20 participants, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267642, a Phase 2 study of Psoriatic Arthritis, has completed, sponsored by AbGenomics B.V Taiwan Branch.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.
Conditions Studied
Interventions
- BIOLOGICAL AbGn-168H
Study Locations (7)
California
- UC San Diego - La Jolla
- Stanford University - Palo Alto
Florida
- Sarasota Arthritis Research Center - Sarasota
Illinois
- Northwestern University - Chicago
Michigan
- Justus J. Fiechtner, MD, PC - Lansing
Texas
- Metroplex Clinical Research Center, LLC - Dallas
Washington
- Seattle Rheumatology Associates/Swedish Clinical Research - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT02267642 record still lists
NCT02267642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which AbGn-168H is the first listed.
NCT02267642 lists 7 locations in 6 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT02267642 about?
NCT02267642 is a clinical study titled "A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis". To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.
What is the current status of trial NCT02267642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-01. Estimated completion is 2016-01.
What conditions does trial NCT02267642 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT02267642?
The interventions under investigation include: AbGn-168H (BIOLOGICAL).
Who is sponsoring clinical trial NCT02267642?
This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02267642 being conducted?
This trial has 7 study locations across California, Florida, Illinois, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02267642's enrollment target sits among peer trials
20 46th of 48 higher than 1 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
RECRUITING · Phase 2
-
Impact of Literacy Level on Patient Education and Health Among People With Arthritis
COMPLETED · Phase 2
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia